Table 5.
Ingenuity pathway analysis revealed 62 anterior cingulate cortex pathways were significantly enriched by chronic binge alcohol administration (p < 0.05)
| Ingenuity canonical pathway | Molecules | Z-score | P-value |
|---|---|---|---|
|
| |||
| ABRA Signaling Pathway | ACTA2, ACTB, ACTC1, CALD1, GSN, MYH11, MYL9, TAGLN, TPM1, TPM2, VCL | 2.111 | 0.000 |
| Actin Cytoskeleton Signaling | ACTA2, ACTB, ACTC1, ACTN4, APC, ARHGEF6, FGF12, FLNA, FN1, GSN, MYH11, MYL12B, MYL9, RRAS, TLN1, VCL | 2.138 | 0.000 |
| Acute Phase Response Signaling | ALB, APOA1, APOA2, C1QB, CRABP1, FN1, FTL, RRAS, SERPINA3, TTR, VWF | 0.816 | 0.000 |
| Agrin Interactions at Neuromuscular Junction | ACTA2, ACTB, ACTC1, ARHGEF6, PKLR, RRAS | 1.342 | 0.000 |
| Amyloid fiber formation | APOA1, GSN, MFGE8, TTR | 2 | 0.002 |
| Atherosclerosis Signaling | ALB, APOA1, APOA2, APOD, COL18A1 | 2.236 | 0.002 |
| Autism Signaling Pathway | ALDH18A1, ALDH3B1, ALDH4A1, APC, FMR1, RRAS | −0.816 | 0.019 |
| Binding and Uptake of Ligands by Scavenger Receptors | ALB, APOA1, COL4A1, COL4A2, FTL, HBB | 2.449 | 0.000 |
| Caveolar-mediated Endocytosis Signaling | ACTA2, ACTB, ACTC1, ALB, CAVIN1, FLNA | 2 | 0.000 |
| Cell junction organization | ACTB, ARHGEF6, FLNA, NECTIN3, RSU1 | 1.342 | 0.000 |
| Deubiquitination | ACTB, APC, PSME1, PSME2, RNF123, WDR20 | 0 | 0.009 |
| DHCR24 Signaling Pathway | ALB, APOA1, APOA2, APOD, RRAS, TTR | 2.449 | 0.000 |
| Dilated Cardiomyopathy Signaling Pathway | ACTA2, ACTB, ACTC1, CAMK1, CAMK4, CNN1, DES, GAB1, MYH11, MYL9, TPM1 | −1.667 | 0.000 |
| EPH-Ephrin signaling | ACTB, MYH11, MYL12B, MYL9 | 2 | 0.004 |
| Epithelial Adherens Junction Signaling | MYL12B, NECTIN3, RRAS, VCL | 1 | 0.022 |
| Extracellular matrix organization | BGN, COL18A1, COL4A1, COL4A2, FN1, LUM, TTR | 2.646 | 0.000 |
| Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes | ACTA2, ACTB, ACTC1, TLN1 | 2 | 0.004 |
| Gap Junction Signaling | ACTA2, ACTB, ACTC1, CSNK1D, PLCD3, RRAS | 0.816 | 0.023 |
| Glutaminergic Receptor Signaling Pathway (Enhanced) | CAMK4, DGKE, FMR1, PLCD3, SCN4B, VAMP2 | −0.816 | 0.023 |
| Glycerophospholipid biosynthesis | CHKB, GPCPD1, SLC44A1, STARD10 | −2 | 0.005 |
| GP6 Signaling Pathway | COL18A1, COL4A1, COL4A2, TLN1 | 2 | 0.011 |
| Hepatic Fibrosis Signaling Pathway | ACTA2, APC, CSNK1D, FTL, MYL12B, MYL9, RRAS | 2.236 | 0.023 |
| ILK Signaling | ACTA2, ACTB, ACTC1, ACTN4, ARHGEF6, FLNA, FN1, MYH11, MYL9, RSU1, TGFB1I1, VCL | 1.155 | 0.000 |
| Integrin cell surface interactions | COL18A1, COL4A1, COL4A2, FBN1, FN1, LUM, VWF | 2.646 | 0.000 |
| Integrin Signaling | ACTA2, ACTB, ACTC1, ACTN4, GSN, MYL12B, MYL9, RRAS, TLN1, VCL | 3 | 0.000 |
| L1CAM interactions | ACTB, ANK3, LYPLA2, NRP2, SCN4B, SPTBN4 | −1.633 | 0.000 |
| Leukocyte Extravasation Signaling | ACTA2, ACTB, ACTC1, ACTN4, TIMP3, VCL | 1.342 | 0.002 |
| LXR/RXR Activation | ALB, APOA1, APOA2, APOD, TTR | 2.236 | 0.002 |
| Neutrophil degranulation | AGL, ALDH3B1, CNN2, FTL, GSN, HBB, S100A11, SER-PINA3, SNAP23, TMT1A, TTR, VCL |
2.309 | 0.000 |
| Nuclear Cytoskeleton Signaling Pathway | ACTA2, ACTB, ACTC1, DES, FN1 | 2.236 | 0.017 |
| PAK Signaling | ARHGEF6, MYL12B, MYL9, RRAS | 1 | 0.008 |
| Parkinson’s Signaling Pathway | ACTA2, ACTB, ACTC1, ALDH18A1, ALDH3B1, ALDH4A1 | −2.449 | 0.018 |
| Paxillin Signaling | ACTA2, ACTB, ACTC1, ACTN4, ARHGEF6, RRAS, TLN1, VCL | 2.121 | 0.000 |
| Post-translational protein phosphorylation | ALB, APOA1, APOA2, FBN1, FN1, MFGE8, VWA1 | 2.646 | 0.000 |
| Production of Nitric Oxide and Reactive Oxygen Species in Macrophages | ALB, APOA1, APOA2, APOD | 2 | 0.041 |
| Protein Kinase A Signaling | FLNA, MTMR7, MYL12B, MYL9, PDE4B, PLCD3, PYGM | −1 | 0.022 |
| Pulmonary Fibrosis Idiopathic Signaling Pathway | ACTA2, ACTB, ACTC1, COL18A1, COL4A1, COL4A2, FN1, RRAS | 2.449 | 0.002 |
| RAF/MAP kinase cascade | ACTB, FN1, NEFL, PSME1, PSME2, SPTBN4, TLN1, VCL, VWF | 1.667 | 0.000 |
| Regulation of Actin-based Motility by Rho | ACTA2, ACTB, ACTC1, GSN, MYL12B, MYL9 | 2.236 | 0.000 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by IGFBPs | ALB, APOA1, APOA2, FBN1, FN1, MFGE8, VWA1 | 2.646 | 0.000 |
| Response to elevated platelet cytosolic Ca2 + | ACTN4, ALB, APOA1, FLNA, FN1, SERPINA3, TIMP3, TLN1, VCL, VWF | 3.162 | 0.000 |
| RHO GTPase cycle | ACTB, ACTC1, ARHGAP39, ARHGEF6, CAVIN1, CDC42SE2, CHN1, SNAP23, TEX2, WIPF3 |
0.632 | 0.001 |
| RHO GTPases activate PAKs | FLNA, MYH11, MYL12B, MYL9 | 2 | 0.000 |
| RHOA Signaling | ACTA2, ACTB, ACTC1, MYL12B, MYL9, NRP2 | 2.236 | 0.000 |
| RHOGDI Signaling | ACTA2, ACTB, ACTC1, ARHGEF6, MYH11, MYL12B, MYL9 | −1.633 | 0.001 |
| RNA Polymerase II Transcription | POLR2B, RNMT, SNRPE, SRSF6 | −2 | 0.019 |
| Role of Osteoclasts in Rheumatoid Arthritis Signaling Pathway | CAMK4, COL18A1, COL4A1, COL4A2, GSN, RRAS | 1.633 | 0.019 |
| Semaphorin interactions | MYH11, MYL12B, MYL9, RRAS, TLN1 | 2.236 | 0.000 |
| Semaphorin Neuronal Repulsive Signaling Pathway | MYL12B, MYL9, NRP2, PDE4B, RRAS | −0.447 | 0.004 |
| Sertoli Cell-Germ Cell Junction Signaling Pathway (Enhanced) | ACTA2, ACTB, ACTC1, NECTIN3, RRAS | −1.342 | 0.022 |
| Sertoli Cell-Sertoli Cell Junction Signaling | ACTA2, ACTB, ACTC1, ACTN4, NECTIN3, RRAS, VCL | 2.646 | 0.001 |
| Signaling by Rho Family GTPases | ACTA2, ACTB, ACTC1, ARHGEF6, DES, MYL12B, MYL9 | 1.89 | 0.002 |
| Smooth Muscle Contraction | ACTA2, CALD1, MYH11, MYL12B, MYL9, TLN1, TPM1, TPM2, VCL | 3 | 0.000 |
| SNARE Signaling Pathway | MYH11, MYL9, SNAP23, SYN3, VAMP2 | 2.236 | 0.002 |
| Striated Muscle Contraction | ACTC1, DES, TPM1, TPM2 | 2 | 0.000 |
| Synaptogenesis Signaling Pathway | CHN1, NECTIN3, RRAS, SYN3, TLN1, VAMP2 | 0.816 | 0.020 |
| Thrombin Signaling | ARHGEF6, CAMK1, CAMK4, MYL12B, MYL9, PLCD3, RRAS | −0.447 | 0.001 |
| VEGF Signaling | ACTA2, ACTB, ACTC1, ACTN4, RRAS, VCL | 1.633 | 0.000 |
| Virus Entry via Endocytic Pathways | ACTA2, ACTB, ACTC1, FLNA, RRAS | 2.236 | 0.001 |
| Wound Healing Signaling Pathway | ACTA2, COL18A1, COL4A1, COL4A2, FN1, RRAS | 2.449 | 0.007 |
| Xenobiotic Metabolism AHR Signaling Pathway | ALDH18A1, ALDH3B1, ALDH4A1, NQO2 | −2 | 0.003 |
| Xenobiotic Metabolism CAR Signaling Pathway | ALDH18A1, ALDH3B1, ALDH4A1, SOD3 | −1 | 0.043 |